Cogent Biosciences, Inc. Financing Cash Flow
Cogent Biosciences, Inc. (COGT) reported Financing Cash Flow of $55.49 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-10
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.96M, a 93.74% decline year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $52.54M, a 110.40% increase year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $588.67M, a 2264011.54% increase year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $217.37M, a 34734.46% increase year-over-year.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2025 was $878.23M, a 309.53% increase from fiscal 2024.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2024 was $214.45M, a 31.13% increase from fiscal 2023.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2023 was $163.54M, a 0.01% decline from fiscal 2022.
- Cogent Biosciences, Inc. net cash provided by (used in) financing activities for fiscal 2022 was $163.56M, a 330.69% increase from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $55.49M 10-Q · filed 2026-08-10 | $644.16M derived: sum of 3 quarters · filed 2026-08-10 | $861.53M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $52.54M 10-Q · filed 2026-05-05 | $641.21M derived: sum of 2 quarters · filed 2026-05-05 | $858.57M derived: sum of 3 quarters · filed 2026-05-05 | $905.80M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $588.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $806.04M derived: sum of 2 quarters · filed 2026-02-17 | $853.26M derived: sum of 3 quarters · filed 2026-08-10 | $878.23M 10-K · filed 2026-02-17 |
| 2025-09-30 | $217.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $264.59M derived: sum of 2 quarters · filed 2026-08-10 | $289.56M 10-Q · filed 2025-11-07 | $289.59M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $47.23M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $72.20M 10-Q · filed 2026-08-10 | $72.22M derived: sum of 3 quarters · filed 2026-08-10 | $72.85M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $24.97M 10-Q · filed 2026-05-05 | $25.00M derived: sum of 2 quarters · filed 2026-05-05 | $25.62M derived: sum of 3 quarters · filed 2026-05-05 | $25.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $26.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $650.00K derived: sum of 2 quarters · filed 2026-02-17 | $394.00K derived: sum of 3 quarters · filed 2026-02-17 | $214.45M 10-K · filed 2026-02-17 |
| 2024-09-30 | $624.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $368.00K derived: sum of 2 quarters · filed 2025-11-07 | $214.43M 10-Q · filed 2025-11-07 | $214.43M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-06-30 | -$256.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $213.80M 10-Q · filed 2025-08-05 | $213.80M derived: sum of 3 quarters · filed 2026-02-17 | $214.80M derived: sum of 4 quarters · filed 2026-02-17 |
| 2024-03-31 | $214.06M 10-Q · filed 2025-05-06 | $214.06M derived: sum of 2 quarters · filed 2026-02-17 | $215.06M derived: sum of 3 quarters · filed 2026-02-17 | $377.15M derived: sum of 4 quarters · filed 2026-02-17 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-17 | $1.00M derived: sum of 2 quarters · filed 2026-02-17 | $163.09M derived: sum of 3 quarters · filed 2026-02-17 | $163.54M 10-K · filed 2026-02-17 |
| 2023-09-30 | $1.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $163.09M derived: sum of 2 quarters · filed 2024-11-12 | $163.54M 10-Q · filed 2024-11-12 | $163.85M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-06-30 | $162.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $162.54M 10-Q · filed 2024-08-06 | $162.85M derived: sum of 3 quarters · filed 2025-02-25 | $163.84M derived: sum of 4 quarters · filed 2025-02-25 |
| 2023-03-31 | $445.00K 10-Q · filed 2024-05-07 | $760.00K derived: sum of 2 quarters · filed 2025-02-25 | $1.75M derived: sum of 3 quarters · filed 2025-02-25 | $163.87M derived: sum of 4 quarters · filed 2025-02-25 |
| 2022-12-31 | $315.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.30M derived: sum of 2 quarters · filed 2025-02-25 | $163.42M derived: sum of 3 quarters · filed 2025-02-25 | $163.56M 10-K · filed 2025-02-25 |
| 2022-09-30 | $990.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $163.10M derived: sum of 2 quarters · filed 2023-11-07 | $163.24M 10-Q · filed 2023-11-07 | $201.25M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $162.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $162.25M 10-Q · filed 2023-08-08 | $200.26M derived: sum of 3 quarters · filed 2024-02-26 | $200.31M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $138.00K 10-Q · filed 2023-05-09 | $38.14M derived: sum of 2 quarters · filed 2024-02-26 | $38.20M derived: sum of 3 quarters · filed 2024-02-26 | $38.20M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $38.01M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $38.06M derived: sum of 2 quarters · filed 2024-02-26 | $38.06M derived: sum of 3 quarters · filed 2024-02-26 | $37.98M 10-K · filed 2024-02-26 |
| 2021-09-30 | $55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $55.00K derived: sum of 2 quarters · filed 2022-11-14 | -$30.00K 10-Q · filed 2022-11-14 | $122.11M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$85.00K 10-Q · filed 2022-08-09 | $122.05M derived: sum of 3 quarters · filed 2022-08-09 | $231.98M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | -$85.00K 10-Q · filed 2022-05-10 | $122.05M derived: sum of 2 quarters · filed 2022-05-10 | $231.98M derived: sum of 3 quarters · filed 2022-05-10 | $232.04M derived: sum of 4 quarters · filed 2022-05-10 |
| 2020-12-31 | $122.14M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $232.06M derived: sum of 2 quarters · filed 2022-03-15 | $232.12M derived: sum of 3 quarters · filed 2022-03-15 | $232.20M 10-K · filed 2022-03-15 |
| 2020-09-30 | $109.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $109.99M derived: sum of 2 quarters · filed 2021-11-10 | $110.06M 10-Q · filed 2021-11-10 | $110.06M derived: sum of 4 quarters · filed 2021-11-10 |
| 2020-06-30 | $62.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $135.00K 10-Q · filed 2021-08-16 | $135.00K derived: sum of 3 quarters · filed 2021-08-16 | $135.00K derived: sum of 4 quarters · filed 2021-08-16 |
| 2020-03-31 | $73.00K 10-Q · filed 2021-05-12 | $73.00K derived: sum of 2 quarters · filed 2021-05-12 | $73.00K derived: sum of 3 quarters · filed 2021-05-12 | $170.00K derived: sum of 4 quarters · filed 2021-05-12 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $0.00 derived: sum of 2 quarters · filed 2021-03-16 | $97.00K derived: sum of 3 quarters · filed 2021-03-16 | $108.00K 10-K · filed 2021-03-16 |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $97.00K derived: sum of 2 quarters · filed 2020-11-09 | $108.00K 10-Q · filed 2020-11-09 | $503.00K derived: sum of 4 quarters · filed 2020-11-09 |
| 2019-06-30 | $97.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | $108.00K 10-Q · filed 2020-08-11 | $503.00K derived: sum of 3 quarters · filed 2020-08-11 | $678.00K derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $11.00K 10-Q · filed 2020-05-11 | $406.00K derived: sum of 2 quarters · filed 2020-05-11 | $581.00K derived: sum of 3 quarters · filed 2020-05-11 | $70.89M derived: sum of 4 quarters · filed 2020-05-11 |
| 2018-12-31 | $395.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $570.00K derived: sum of 2 quarters · filed 2020-03-26 | $70.88M derived: sum of 3 quarters · filed 2020-03-26 | $70.35M 10-K · filed 2020-03-26 |
| 2018-09-30 | $175.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $70.49M derived: sum of 2 quarters · filed 2019-11-12 | $69.95M 10-Q · filed 2019-11-12 | $69.22M derived: sum of 4 quarters · filed 2019-11-12 |
| 2018-06-30 | $70.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-12 | $69.78M 10-Q · filed 2019-08-12 | $69.04M derived: sum of 3 quarters · filed 2019-08-12 | |
| 2018-03-31 | -$535.00K 10-Q · filed 2019-05-13 | -$1.27M derived: sum of 2 quarters · filed 2019-05-13 | ||
| 2017-12-31 | -$734.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-28 | -$729.00K 10-K · filed 2019-03-28 | ||
| 2017-09-30 | $5.00K 10-Q · filed 2018-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |